Quest Diagnostics Buys Genetic Testing Company

Quest Diagnostics Buys Genetic Testing Company

by | Jan 27, 2020 12:12 pm | Laboratories, MRI & Dialysis

Quest Diagnostics (NYSE: DGX) broadened its scope in genetics and rare diseases with the January 22 acquisition of Blueprint Genetics, based in Helsinki, Finland. Founded in 2012, the target now serves customers in more than 70 countries. Financial terms of the all-cash equity transaction were not disclosed. Blueprint is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. It provides 3,900 targeted single gene and more than 200 panel tests spanning 14 medical specialties. Its growth comes largely from its proprietary guideline-supported methods of gene variant interpretation... Read More »
Quest Diagnostics Inks Two Deals in One Week

Quest Diagnostics Inks Two Deals in One Week

by | Sep 27, 2018 12:22 pm | Laboratories, MRI & Dialysis

Quest Diagnostics (NYSE: DGX) had a busy week in late September, announcing two acquisitions. On September 25, Quest announced its purchase of the U.S. laboratory services business of Oxford Immunotec Global plc in Abingdon, UK. The U.S.-based business includes the T-SPOT.TB tuberculosis and the Accutix tick-borne disease testing services in Memphis, Tennessee and Norwood, Massachusetts. As part of the transaction, Oxford Immunotec will sell T-SPOT.TB test kits and related accessories to Quest under the terms of a long-term supply agreement, which would be effective at closing of the acquisition some time in the fourth quarter of 2018. Two days later, Quest went in a different direction... Read More »